Investors greet what on the surface appears to be good news for Triangle-based TransEnterix with a seesaw day of trading for the developer of robotic surgery technology. Does good news on FDA filing and capital funding end takeover rumors?

TransEnterix (NYSE MKT: TRXC) triggered a big jump in its shares early Wednesday with the news that it had completed a response to the FDA about its SurgiBot system. The company said it hopes to gain FDA approval in the first quarter.

Having utilized an earlier credit facility of $25 million, TransEnterix also said it planned to raise up to $43.6 million.

“We are pleased to have completed our response to the FDA and strengthened our balance sheet,” said TransEnterix CEO, Todd Pope in a statement. “We continue to expect FDA clearance for the SurgiBot System in the first quarter of this year, and our cash position allows us to accelerate our transition to commercializing both the ALF-X and the SurgiBot.”

The mix of news seemed to quiet – at least for the time being – rumors that Johnson & Johnson might buy the company. Acquisition talk has been circulating for two weeks.

“Investors believe that Johnson & Johnson (JNJ) might acquire the company,” reported on Jan. 28 when TransEnterix shares surged 15 percent.

As a result of Wednesday’s news mix shares fluctuated near their 52-week high of $4.87 by hitting a peak of $4.79. But a sharp sell-off followed.

By the day’s close, TransEnterix was down 4.32 percent at $4.21.